123P Combination potential of EO-3021, a CLDN18.2 vc-MMAE ADC, with VEGFR2 or PD1 inhibition in preclinical models of CLDN18.2-expressing cancers
Conclusions: In this study population, the addition of antieIL-8 to NIVO + IPI was well tolerated, but no statistically significant difference for the primary endpoint of ORR or the secondary endpoint of PFS was observed in patients with advanced melanoma who had progressed on/after anti-PD-(L)1 therapy.Clinical trial identification: NCT03400332.
Authors
- David Dornan
- John L. Cleveland (ORCID: https://orcid.org/0000-0002-7561-9065)
- Valerie M. Jansen (ORCID: https://orcid.org/0009-0002-5754-6111)
- Thomas O’Hare
Institutions
- Valore (United States) (US)
Publication Details
- Journal
- Immuno-Oncology Technology
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1016/j.iotech.2024.100752
- Primary Topic
- Cancer Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- AstraZeneca
- PharmaMar
- CRIS Cancer Foundation